Recordati Releases 2024 Financial Documentation Ahead of Shareholders’ Meeting

Story Highlights
  • Recordati is a global pharmaceutical group offering specialty and general medicine.
  • Recordati has released its 2024 financial reports ahead of the April 2025 shareholders’ meeting.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Recordati Releases 2024 Financial Documentation Ahead of Shareholders’ Meeting

Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) just unveiled an announcement.

Recordati has announced the availability of its 2024 Annual Financial Report, including the Draft Financial Statements and Consolidated Financial Statements as of December 31, 2024, along with various management and audit reports. These documents, approved by the Board of Directors, are accessible to the public via the company’s headquarters, website, and authorized storage mechanism. This release is part of the preparations for the Ordinary Shareholders’ Meeting scheduled for April 29, 2025, highlighting the company’s commitment to transparency and governance.

More about Recordati Industria Chimica e Farmaceutica SPA

Recordati is an international pharmaceutical group listed on the Italian Stock Exchange, with origins in a family pharmacy in Northern Italy in the 1920s. The company offers therapeutic options in specialty and general medicine, as well as in rare diseases, and operates in about 150 countries across the EMEA, Americas, and APAC regions with over 4,450 employees.

YTD Price Performance: 5.04%

Average Trading Volume: 34,046

Technical Sentiment Signal: Sell

Current Market Cap: €10.97B

See more insights into REC stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App